{"organizations": [], "uuid": "a685375bd33207f9eadb2a0b33c7a4b13b52ee50", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180226.html", "section_title": "Archive News &amp; Video for Monday, 26 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-summit-therapeutics-announces-anal/brief-summit-therapeutics-announces-analysis-showing-ezutromid-significantly-reduced-muscle-inflammation-in-phase-2-clinical-trial-idUSFWN1QG0T9", "country": "US", "domain_rank": 408, "title": "BRIEF-Summit Therapeutics ‍Announces Analysis Showing Ezutromid Significantly Reduced Muscle Inflammation In Phase 2 Clinical Trial", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.997, "site_type": "news", "published": "2018-02-26T20:07:00.000+02:00", "replies_count": 0, "uuid": "a685375bd33207f9eadb2a0b33c7a4b13b52ee50"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-summit-therapeutics-announces-anal/brief-summit-therapeutics-announces-analysis-showing-ezutromid-significantly-reduced-muscle-inflammation-in-phase-2-clinical-trial-idUSFWN1QG0T9", "ord_in_thread": 0, "title": "BRIEF-Summit Therapeutics ‍Announces Analysis Showing Ezutromid Significantly Reduced Muscle Inflammation In Phase 2 Clinical Trial", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 26 (Reuters) - Summit Therapeutics Plc:\n* ‍ANNOUNCES NEW ANALYSIS SHOWING EZUTROMID SIGNIFICANTLY REDUCED MUSCLE INFLAMMATION IN PHASE 2 CLINICAL TRIAL IN DMD​\n* ‍MRS-T2 DATA PROVIDE EVIDENCE OF EARLY IMPACT OF EZUTROMID ON DOWNSTREAM MUSCLE HEALTH​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-26T20:07:00.000+02:00", "crawled": "2018-02-27T15:08:06.070+02:00", "highlightTitle": ""}